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COPDBackground: The prevalence of abdominal aortic aneurysm is high in chronic obstructive pulmonary disease
(COPD) population. Emphysema involves proteolytic destruction of elastic fibers. Therefore, emphysema may
also contribute to thoracic aorta dilatation. This study assessed aorta dilation in smokers stratified by presence
of COPD, emphysema and airway thickening.
Methods: Aorta diameters were measured on 3Dmagnetic resonance angiography in smokers recruited from the
Multi-Ethnic Study of Atherosclerosis (MESA), the Emphysema and Cancer Action Project (EMCAP), and the local
community. COPD was defined by standard spirometric criteria; emphysema was measured quantitatively on
computed tomography and bronchitis was determined from medical history.
Results: Participants (n = 315, age 58–79) included 150 with COPD and 165 without COPD, of whom 56% and
19%, respectively, had emphysema. Subjects in the most severe quartile of emphysematous change showed
the largest diameter at all four aorta locations compared to those in the least severe quartiles (all p < 0.001).
Comparing subjects with andwithout COPD, aorta diameters were larger in participants with severe COPD in as-
cending and arch (both p < 0.001), and abdominal aorta (p = 0.001). Chronic bronchitis and bronchial wall
thickness did not correlate with aorta diameter. In subjects with emphysema, subjects with coexistence of
COPD showed larger aorta than those without COPD in ascending (p=0.003), arch (p=0.002), and abdominal
aorta (p = 0.04).
Conclusions: This study showed larger aorta diameter in subjectswith COPD and severe emphysema compared to
COPD related to chronic bronchitis or bronchial wall thickening.
© 2021 Elsevier B.V. All rights reserved.AHA, American College of Cardiology/American Heart Association; ACE, Angiotensin-converting enzyme; ARB, Angiotensin II re-
ructive pulmonary disease; CT, Computed Tomography; EMCAP, Emphysema and Cancer Action Project; FEV1, forced expiratory
d vital capacity; Gd, gadolinium; HDL, high-density lipoprotein; ICC, Infraclass Correlation Coefficient; IQR, Interquartile range;
e; MMP, Metalloproteninases; MRI, magnetic resonance imaging; MRA, magnetic resonance angiography; MESA, Multi-Ethnic
-resolved imaging of contrast kinetics (3D time-resolved MRA); TWIST, time-resolved angiography with interleaved stochastic
eliability and freedom, from bias of the data presented and their discussed interpretation.
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Advanced age and smoking are risk factors for aortic aneurysms as
they are for other cardiovascular and pulmonary diseases [1–7]. Other
known risk factors include increased pressure [8], i.e. hypertension or
bicuspid aortic valve jets [1] and diseases thatweaken the aorticwall in-
cluding atherosclerosis [8], Marfan's and other connective tissue dis-
eases [10].
High prevalence of aortic aneurysm is also reported in chronic ob-
structive pulmonary disease (COPD) [11] which is commonly observed
in smokers. COPD is defined by airflow limitation on spirometry that
does not fully reverse [12,13]. Smokingmay also be associatedwith pul-
monary emphysema, chronic bronchitis and airway thickening which
can co-exist with COPD making it difficult to determine which features
are more likely to be associated with aortic aneurysms [14]. This gap in
knowledge is particularly relevant since emphysema and airway thick-
ening can be measured on chest computed tomography (CT). Under-
standing which features are associated with aortic aneurysms could
help potentially guide future screening and prevention strategies.
A striking histological feature of aortic aneurysms is destruction of
the media and elastic tissue from excessive proteolytic enzyme activity
in the aortic wall [2]. Emphysema also involves proteolytic destruction
of elastic fibers. Thus, we hypothesize that both COPD and emphysema
are at increased risk of aneurysm along the entire aorta. To test this hy-
pothesis, we assessed aorta diameters in smokers stratified by presence




The Multi-Ethnic Study of Atherosclerosis (MESA) is a prospective
cohort study that recruited 6814 participants in 2000 to 2002 from
six U.S. communities, who were white, African-American, Hispanic, or
Chinese-American, aged45–84years and freeof clinical cardiovascular dis-
ease. Between 2010 and 2012, 4716 participants returned for follow-up.
The MESA Lung Study enrolled 3965 MESA participants who all
underwent full-lung CT and spirometry in 2010–2012.
The protocols of MESA and all studies described herein were ap-
proved by the Institutional Review Boards of all collaborating institu-
tions (Columbia University, New York, NY; Johns Hopkins University,
Baltimore, MD; Northwestern University, Chicago, IL; University of Cal-
ifornia, Los Angeles, LA; University of Minnesota, Twin Cities, MN; Uni-
versity of Iowa, Iowa City, IA) [15].
The population of this study was created from three cohorts: 1) all
the subjects with COPD or emphysema from the MESA Lung Study
(n=190) [16], 2) all participants from the Emphysema and Cancer Ac-
tion Project (EMCAP), a nonoverlapping lung cancer screening study
(n = 89) [17], and 3) outpatient community at Columbia University
Medical Center (n=36), as described in previous studies [18,19]. Inclu-
sion criteria were 50–79 years of age with ≥10 pack-year smoking his-
tory. Exclusion criteria were clinical cardiovascular disease
(myocardial infarction, angina, heart failure, valve disease, atrialfibrilla-
tion or stroke), stage IIIb-V chronic kidney disease, asthma prior to age
45 years, prior lung resection, cancer, allergy to gadolinium, claustro-
phobia, metal in the body, pregnancy, andweight > 300lbs. The present
report includes these 315 participants who all underwent spirometry,
CT scanning and contrast-enhanced cardiopulmonary magnetic reso-
nance imaging (MRI) including three dimensional (3D) time-resolved
magnetic resonance angiography (MRA, TRICKS or TWIST).
2.1.1. Study oversight
Study procedures were approved by institutional review boards of
the participating institutions, Columbia University Medical Center
(AAAD6395), Johns Hopkins University (NA_00030361/CR00017844),215Northwestern University (STU00021057-MOD0031), University of Cal-
ifornia, Los Angeles (11–002392-AM-00051), University of Washington
(STUDY00001485), and by theNational Heart, Lung, andBlood Institute.
Written informed consent was obtained from all participants.
2.2. Magnetic resonance imaging
The MRI protocol included time-resolved 3D MRA to assess pulmo-
nary vasculature [18]. Images were obtained using a 1.5 Tesla whole-
body MRI system (Signa LX, GE Healthcare or Avanto, Siemens).
TRICKS or TWIST was performed at 1.5 s temporal resolution following
injection of 0.1 mMol/kg of Gd (Gd:DTPA, Bayer, Wayne, NY), and coro-
nal 3D image of the aorta was obtained from cranial to aortic arch and
caudal to aortic bifurcation.
2.2.1. Aorta assessment
MRA images were evaluated for the diameter of ascending aorta at
the level of pulmonary artery, aortic arch at the level of brachiocephalic
artery, intrathoracic descending aorta at the level of pulmonary artery,
the abdominal aorta at the level of the mesenteric artery, and the
infrarenal aorta immediately distal to the renal arteries. Aorta diameters
were measured independently by a radiologist and a cardiologist
blinded to all clinical information about the subjects using electronic
calipers on a computerworkstationwith 3Dvisualization software (vol-
ume Viewer Plus Suite 15.10.4 on Advantage Windows Workstation
(GE Medical Systems, Waukesha, WI). Reliability and interobserver
agreement between the two readers were assessed by intraclass corre-
lation coefficient (ICC). Discrepancies between the observers were re-
solved with a secondary consensus reading.
2.3. COPD case status
We used the standard definition of COPD to define case status: a
post-bronchodilator ratio of the forced expiratory volume in one second
(FEV1) to the forced vital capacity (FVC) ratio < 0.70 [13,20] (Supple-
mental Fig. 1). Post-bronchodilator spirometry wasmeasured in all par-
ticipants based on American Thoracic Society/European Respiratory
Society guidelines. Rolling barrel spirometer was used as previously de-
scribed in the MESA Lung protocol [21]. COPD severity was classified as
mild, FEV1 ≥ 80% predicted; moderate, FEV1 50% to 79% predicted; and
severe, FEV1 < 50% predicted [22].
2.4. Computed tomography (CT), assessment of emphysema and airway
anatomy
All participants underwent full-lung CT scans with breath holding at
maximum inspiration without intravenous contrast and reconstructed
using a high-spatial-contrast algorithm with 0.625-mm-slice thickness
on Siemens and GE 64-slice scanners (GE Healthcare, Waukesha, WI).
All scans were acquired following the SPIROMICS protocol [16,17,23,31].
Image attenuation was assessed using a modified version of the Pul-
monary Analysis Software Suite (VIDA Diagnostics, Coralville, IA) at a
single reading center by trained readers without knowledge of other
participants' information. Emphysema-like lung (also known as percent
low attenuation area and hereafter referred to as percent emphysema)
was defined as the number of lung voxels with outside-air corrected at-
tenuation less than −950 Hounsfield units on chest CT [24] (Supple-
mental Table 1).
Stratified analyses defined patients with emphysema as those with
percent emphysema voxels above themedian value in this study. Sensi-
tivity analyses used alternate thresholds of 25th percentile, as well as
median of emphysema [25].
The central airway tree was identified using Apollo Software (VIDA
Diagnostics, Coralville, IA). Segmentation and labelling of the airways
were visually verified by an image analyst and all labelled airways
were assigned a generation number based upon the number of branch
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lumen area were measured at the 5th generation perpendicular to the
local airway segment's long axis and measurements were averaged
along the middle third of each labelled airway segment [26].
Chronic bronchitis was defined as a chronic productive cough for 3
or more months in two or more years [21].2.5. Anthropometry, smoking status and other covarieties
Age, gender, race/ethnicity, educational attainment, smoking status,
pack-years, and medical history were self-reported. Medication use
was assessed by medication inventory. Height and weight were mea-
sured following theMESA protocol [3]. Resting blood pressure was mea-
sured 3 times in the seated position. Glucose, total cholesterol and high-
density lipoprotein (HDL) cholesterol levels, and complete blood counts
were measured from blood samples after at least twelve hour of fasting.
Low-density lipoprotein (LDL) cholesterol level was calculated using the
Friedewald equation [27]. Smoking history was assessed using standard
questionnaire items andwas confirmedwith plasma cotinine levels [28].
Study participants reporting at least 1 cigarette in the 30 days prior to as-
sessment were classified as current smokers. Information onmedication
use was obtained by medication inventory. Diabetes was defined as a
fasting plasma glucose ≥126 mg/dL or self-report of physician diagnosis.
Hypertensionwas defined as systolic blood pressure (Psys) ≥ 140mmHg,Table 1





Age, mean ± SD, years 66 ± 7






Educational attainment, N (%)
≤ High school degree 24 (30)
Some college/Assoc. degree/Vocational school 25 (32)
≥ College degree 30 (38)
Hypertension, N (%) 36 (46)
Diabetes Mellitus, N (%) 12 (15)
Smoking status, N (%)
Current 29 (37)
Former 50 (63)
Pack-years of smoking, median [IQR] 32 [20–46]
Characteristics
Height, mean ± SD, cm 165 ± 10
Weight, mean ± SD, kg 78 ± 17
Body mass index, mean ± SD, kg/m2 28 ± 5
Body surface area, mean ± SD, m2 1.8 ± 0.22
Systolic blood pressure, mean ± SD, mmHg 122 ± 17
Diastolic blood pressure, mean ± SD, mmHg 70 ± 10
MAP, mean ± SD, mmHg 87 ± 11
PP, mean ± SD, mmHg 51 ± 15
Labs
Cotinine levels, mean ± SD, mg/dL 133 ± 211
LDL, mean ± SD, mg/dL 106 ± 31
HDL, mean ± SD, mg/dL 58 ± 20
Triglycerides, mean ± SD, mg/dL 101 ± 44
Cholesterol, median [IQR] 178 [160–205]
Pulmonary function test
FEV1 percent of predicted, mean ± SD 91 ± 17
FVC percent of predicted, mean ± SD 92 ± 13
FEV1/FVC ratio, mean ± SD 0.75 ± 0.09
Definition of abbreviations: FVC= forced vital capacity; FEV1 = forced expiratory volume in 1
HU) = percentage of emphysema-like lung at−950 Hounsfield units; PP = Pulse Pressure.
216diastolic blood pressure (Pdiast) ≥ 90 mmHg or physician diagnosis. The
Mean Arterial Pressure (MAP) was calculated using the systolic and dia-
stolic pressure values in the equation (Pdiast + 1/3 (Psys - Pdias)), and the
Pulse Pressure (PP) as the difference between the systolic and diastolic
pressure readings. All the blood pressure associated values were mea-
sured in mmHg [29].2.6. Statistical analysis
Dichotomous variables are presented as proportions and continuous
variables as means with standard deviation unless otherwise indicated.
Fisher's exact test was used to assess the significance of differences in the
number of aortic aneurysms based upon in percent emphysema and
COPD severity. Multiple comparisons across levels of COPD severity were
addressed byHolm's step-down procedure. Associations of aorta diameter
with percent emphysema, COPD status and severity, chronic bronchitis
status, and airway anatomy (wall thickness and inner area) were tested
with linear regression. Potential confounderswere selected based uponbi-
ological plausibility and examinationof correlationswith covariates. Unad-
justed and adjusted linear regression models were performed, controlling
for age, gender, race/ethnicity, height, weight, body surface area (BSA), co-
hort, smoking status, blood pressure, LDL-Cholesterol, HDL-Cholesterol
and triglycerides, diabetes, smoking status, cotinine levels, and pack-
years smoked [30]. Given that study participants were recruited based50 HU)
2nd Quartile 3rd Quartile 4th Quartile
n = 79 n = 79 n = 78
69 ± 6 68 ± 7 69 ± 7
44 (56) 53 (67) 55 (70)
39 (49) 46 (58) 50 (64)
3 (4) 6 (8) 3 (4)
22 (28) 17 (21) 20 (26)
15 (19) 10 (13) 5 (6)
12 (24) 16 (20) 17 (22)
20 (25) 27 (34) 20 (26)
40 (51) 36 (45) 41 (52)
33 (42) 40 (51) 36 (46)
12 (15) 11 (14) 10 (13)
19 (24) 19 (24) 21 (27)
60 (76) 60 (76) 57 (73)
32 [22–48] 32 [19–51] 33 [20–52]
168 ± 10 170 ± 8 171 ± 9
83 ± 18 80 ± 16 78 ± 18
29 ± 5 28 ± 5 27 ± 5
1.9 ± 0.23 1.9 ± 0.20 1.9 ± 0.23
121 ± 18 121 ± 20 122 ± 15
69 ± 9 69 ± 10 72 ± 8
86 ± 10 87 ± 12 89 ± 9
52 ± 15 52 ± 15 49 ± 13
360 ± 2245 88 ± 180 139 ± 647
109 ± 32 110 ± 32 97 ± 31
54 ± 16 58 ± 19 56 ± 18
112 ± 50 109 ± 43 120 ± 84
182 [159–210] 187 [160–222] 178 [147–196]
95 ± 20 92 ± 17 75 ± 25
97 ± 14 101 ± 16 97 ± 18
0.73 ± 0.08 0.69 ± 0.1 0.56 ± 0.14
s; IQR= interquartile range; MAP=Mean Arterial Pressure; Percent emphysema (−950
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physema and other continuous variables were weighted proportionate
to the inverse ratio of the sample prevalence to the source study preva-
lence, COPD cases recruited from the community were assigned the
same weights as cases from EMCAP [31]. A two-tailed P value <0.05 was
considered statistically significant. Analyses were performed using SAS
9.4 (Cary, NC) statistical software.3. Results
The 315 participants had a mean age of 68 ± 7 years old, and 188
(60%) were male. Race/ethnic distribution was 169 (54%) White, 83
(26%) African-American, 44 (14%) Hispanic, and 19 (6%) Asian. All par-
ticipants were either current (n = 88) or former (n = 227) smokers.
Additional demographic data are presented in Table 1.
Intra- and inter-observer agreements of the aorta diameter
measurements are as follows: ascending aorta (ICC=0.71, 0.89, respec-
tively), arch (ICC = 0.72, 0.74, respectively), descending aorta (ICC =
0.75, 0.79, respectively), abdominal aorta (ICC = 0.77, 0.86, respec-
tively), infra-renal aorta (ICC = 0.76, 0.83, respectively).3.1. Aorta diameter and emphysema
Ascending, arch, descending, abdominal and infra-renal aorta diam-
eters were monotonically related to percent emphysema in unadjusted
analyses (Table 2A; all P < 0.001). This positive association of aortic di-
ameterwith percent emphysemawas statistically significant in the fully
adjusted multivariable model (Table 2B, Fig. 1A).
Using ≥40 mm as the threshold for diagnosing ascending aortic an-
eurysm, and ≥ 30 mm for diagnosing abdominal aneurysm, 30 of the
315 participants had aneurysm, with a maximum diameter = 48 mm.
There were 11 aneurysms in the 4th quartile of emphysema severity,
5 in the 3rd quartile, and 11 in the 2nd quartile compared to 3 in the
1st quartile participants. Therefore, in subjects with emphysema, theTable 2
Aorta diameters (mm) according to emphysema quartiles.
(A) Distributions of aorta diameters, by quartile of percent of emphysema-like lung.
Percent of emphysema-like lung
1st Quartile 2nd Quartile
(n = 79) (n = 79)
Normal Borderline
Mean ± SD Mean ± SD
Ascending Aorta 30 ± 3 31 ± 4
Arch 26 ± 2 27 ± 2
Descending Aorta 23 ± 3 24 ± 3
Abdominal Aorta 20 ± 3 21 ± 3
Infrarenal Aorta 14 ± 3 14 ± 3
(B) Adjusted model.
Percent of emphysema-like lung
1st Quartile 2nd Quartile
(n = 79) (n = 79)
Normal Borderline
β (95% CI)
Ascending Aorta Ref 0.71 (−0.29, 1.71)
Arch Ref 0.59 (−0.18, 1.35)
Descending Aorta Ref 0.74 (−0.05, 1.53)
Abdominal Aorta Ref 0.06 (−0.74, 0.87)
Infrarenal Aorta Ref −0.47 (−1.40, 0.46)
Linear regressionmodel adjusted for age, race, gender, cohort, height, weight, BSA, current smok
LDL and diabetes).
217number of aneurysms increased across quartiles (p = 0.04) of emphy-
sema severity (Fig. 1B).3.2. Aorta diameter and COPD severity
Greater severity of COPD was associated with greater diameter of
the ascending aorta, aortic arch, and abdominal aorta (all p-values for
trends across COPD severities categories <0.001), with little changes
after multivariable adjustment (Table 3). Diameters of the aortic arch
and abdominal aorta were significantly greater in severe, moderate
and mild COPD compared to participants with no COPD; the ascending
aorta diameter was significantly greater in severe and moderate COPD
compared to no COPD; and the descending thoracic aorta was signifi-
cantly in greater in diameter in severe COPDonly. Although aortic diam-
eter was greater with COPD, this did not translate into more aortic
aneurysms. Among the 30 total aneurysms, 11were among the 154par-
ticipants without COPD, 8 were among the 53 participants with mild
COPD, 8 were among the 62 subjects with moderate COPD, and 3
were among the 13 individuals with severe COPD, showing no linear re-
lationship (p = 0.2).3.3. Aorta diameter and coexistence of emphysema and COPD
In subjects with emphysema, those with coexistence of COPD
showed greater aorta diameter than those without COPD in ascending
(p=0.003), arch (p=0.002), and abdominal aorta (p=0.04) (Supple-
mental Table 1).3.4. Aorta diameter and chronic bronchitis
Both the unadjusted and adjusted models showed no evidence for a
continuous association of chronic bronchitis with greater aortic diame-
ter (Supplemental Table 2).3rd Quartile 4th Quartile
(n = 79) (n = 78)
Mild Severe
Mean ± SD Mean ± SD p-value
34 ± 3 35 ± 4 <0.001
28 ± 3 29 ± 3 <0.001
27 ± 3 27 ± 3 <0.001
23 ± 3 24 ± 3 <0.001
16 ± 2 17 ± 3 <0.001
3rd Quartile 4th Quartile
(n = 79) (n = 77)
Mild Severe
β (95% CI) β (95% CI) p-value
3.25 (2.26, 4.24) 4.19 (2.98, 5.41) <0.001
1.84 (1.05, 2.64) 2.32 (1.37, 3.26) <0.001
2.80 (2.05, 3.54) 2.86 (2.07, 3.65) <0.001
2.82 (2.00, 3.64) 2.69 (1.84, 3.54) <0.001
1.77 (0.86, 2.68) 2.57 (1.58, 3.57) <0.001
er, pack-years smoked, cardiovascular risk factors (hypertension, cholesterol, triglycerides,
Fig. 1. Patientwith emphysemaMRA post gadolinium TRICKS coronal image. (A) Ecta-sia of the aorta. The ascending aortameasured 4.2 cm, diaphragmatic aorta was 3 cm, and infrarenal
aorta 2 cm ectasia. (B) Aneurysmal ascending aorta.
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Bronchial wall thickness was not associated with any difference in
aorta diameter with the fully adjusted model (Supplemental Table 3).
Furthermore, there was no evidence for a continuous association of
bronchial lumen area and aorta diameter (Supplemental Table 4).
4. Discussion
This large and ethnically diverse population allowed for multiple
stratified analyses of aortic aneurysm risk in COPD according to the
presence of emphysema, chronic bronchitis and bronchial wall thicken-
ing. Among 315 current and former smokers, subjects with COPD and
especially emphysema, diagnosed on CT, showed greater thoracic and
abdominal aorta cross-sectional diameters, compared to controls withTable 3
Aorta diameters (mm) across COPD severity groups.
(A) Distributions of aorta diameters, by COPD severity.
COPD on spirometry
Normal Mild
(n = 165) (n = 61)
Mean ± SD Mean ± SD
Ascending Aorta, 32 ± 4 33 ± 4
Arch 27 ± 3 28 ± 3
Descending Aorta 24 ± 3 26 ± 3
Abdominal Aorta 21 ± 3 22 ± 3




(n = 164) (n = 61)
β (95% CI)
Ascending Aorta, mm Ref 0.98 (−0.16, 2.12)
Arch, mm Ref 1.06 (0.25, 1.87)⁎
Descending Aorta, mm Ref 0.74 (−0.13, 1.61)
Abdominal Aorta, mm Ref 1.11 (0.22, 1.99)⁎
Infrarenal Aorta, mm Ref 1.12 (0.26, 1.98)⁎
Linear regressionmodel adjusted for age, race, gender, cohort, height, weight, BSA, current smok
LDL and diabetes).
⁎ P-value <0.05, indicating statistical significance compared to Normal.
218noCOPD. A greater number of subjectswith severe emphysema showed
thoracic and abdominal aortic aneurysms compared to participants
without emphysema. Increased aorta diameter was not correlated
with chronic bronchitis or airway dimensions.
Aortic aneurysm is the result of multifactorial processes, including
inflammation, genetic abnormalities, biomechanicalwall stress, apopto-
sis, and proteolytic degradation of connective tissue including elastin
and collagen [32,33]. Risk factors for development of aortic aneurysms
include factors that increase stress on the aortic wall (e.g. hypertension
and elevated diastolic blood pressure), factors that promote degrada-
tion of the elastin and collagen fibers within the aorta wall (e.g. aging,
smoking, atherosclerosis), and genetic factors that predispose the aortic
wall to degeneration (e.g. Marfan syndrome, Ehler-Danlos, Cutis Laxa).
Since emphysema also results from destruction of elastin and colla-
gen [34,35], it is not surprising that emphysema is associated withModerate Severe
(n = 70) (n = 19)
Mean ± SD Mean ± SD p-value for trend
33 ± 5 34 ± 4 <0.001
28 ± 3 29 ± 3 <0.001
25 ± 4 26 ± 4 0.11
22 ± 4 24 ± 3 <0.001
16 ± 3 17 ± 3 <0.001
Moderate Severe
(n = 70) (n = 19)
β (95% CI) β (95% CI) p-value for trend
1.60 (0.50, 2.71)⁎ 2.80 (0.74, 4.86)⁎ <0.001
1.09 (0.29, 1.89)⁎ 2.32 (0.85, 3.78)⁎ <0.001
0.81 (−0.04, 1.65) 1.80 (0.23, 3.37)⁎ 0.02
1.14 (0.24, 2.03)⁎ 2.32 (0.72, 3.91)⁎ 0.001
1.15 (0.27, 2.04)⁎ 1.11 (−0.42, 2.65) 0.01
er, pack-years smoked, cardiovascular risk factors (hypertension, cholesterol, triglycerides,
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inhibits the anti-elastase activity of alpha1-antitrypsin (alpha1 - prote-
ase inhibitor), causing an imbalance between elastolytic and
antielastolytic factors, which leads to emphysema [6]. Furthermore, au-
toimmune T-cell activation has been shown to be associated with
smoking in patientswith thoracic aortic aneurysmor dissectionwithout
COPD [37]. Destruction of elastin in aortic aneurysms may be via the
same mechanism.
The relative risk of abdominal aortic aneurysms (AAA) in individuals
who have ever smoked is 2.5 times greater than the relative risk for cor-
onary heart disease [4]. Lederle et al. [5] described AAAmore closely as-
sociated with cigarette smoking than any other tobacco-related disease
except lung cancer. MacSweeney et al. [7] assessed active smoking
(serum cotinine levels), blood pressure, cholesterol, and triglycerides
in patients with small (< 40 mm) AAAs. Active smoking was the only
parameter associated with a significant increase in growth rate, and
double the rate of thoraco-abdominal aneurysm expansion [9]. In
Marfan syndrome [10], subjects are highly predisposed to thoracic aor-
tic aneurysm and/or Type A dissection, with virtually every patient de-
veloping aortic disease at some point during their lifetime [38]. In
addition, giant bullous and emphysema have been reported in Marfan
patients [39]. Cystic medial aortic degeneration also occurs in Ehlers-
Danlos syndrome [40] and in particular the vascular type IV showed
the presence of bullous emphysema and aortic aneurysm [41]. Individ-
uals with Cutis Laxa (generalized elastolysis), characterized by abnor-
mal elastic fibers and loose skin [43], also showed aortic aneurysm
and emphysema [44].
Bicuspid aortic valve is often seen in patients with connective tissue
diseases. The ACC/AHA Valvular Heart Disease Guidelines specifically
address bicuspid aortic valve as a cause of thoraco-abdominal aneurysm
[1], and there are reports of bicuspid aortic valve patients with emphy-
sema [44]. There are also reports of aortic dissection in patients with au-
tosomal dominant polycystic kidney disease [42]. Previous studies
showed a coexistence of polycystic kidney disease and alpha-1
antitrypsin deficiency associated emphysema [45].
The continuous association between greater aortic diameters and
emphysema may also relate to endothelial damage; endothelium is
present in both airways and vessels [46]. Several proinflammatory cyto-
kines, including interleukin-6, interleukin-1β, tumor necrosis factor-α,
and interferon-γ, have been identified in AAAwalls. These cytokines ac-
tivate lymphocytes andmacrophages [32] and promotematrixmetallo-
proteinases MMP-2 and MMP-9 [47] production in the smooth muscle
of aortic wall that degrade elastin and collagen and leads to the cystic
medial necrosis found in aortic aneurysms [37]. These inflammatory
processes are seen in both aneurysms and emphysema [33]. A recent
study in animal models, has showed how treatment with angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II receptor
blockers (ARBs), inhibit transforming growth factor-β in the endothe-
lium, improve endothelial function and restore airspace architecture.
ARB/ACE inhibitor therapy was associated with slower progression of
percent emphysemaover ten years, particularly among former smokers.
ACE and ARB agents are currently being developed for the prevention
and treatment of emphysema [48]. ACE inhibitors are also used in
preventing aortic aneurysm rupture [49].
We used validated instruments including MRA, Spirometry and CT
with data collected in a blinded manner. MRA has an advantage that it
does not risk patients with radiation. Especially for patients requiring
series of imaging tests to follow-up disease processes, cumulative radi-
ation dose via CTmay become somewhat problematic. TRICKS or TWIST
has reasonable temporal and spatial resolution for aortic diameter mea-
surements and allows the visualization of whole aorta with optimal
contrast-enhancement.
There are some limitations in this study. First, our study was obser-
vational and cross-sectional, thus neither causality nor temporality
can be inferred. Secondly, there may be residual confounding factors
that were not included in our models. The study includes a limited age219range, 50–79 years. Aorta diameter had to be obtained from MRA
instead of the higher resolution CT images since the CT was non-
contrast and low dose optimized for assessing lung parenchyma in vol-
unteers not aorta diamter.
5. Conclusions
In this large, multi-ethnic sample of individuals who are former/cur-
rent smokers free of clinical cardiovascular disease recruited from the
community, we have found that COPD with emphysema is associated
with increased thoracic and abdominal aortic diameters but this is not
observed in the chronic bronchitis and thickened airway subtypes of
COPD. Theremay be similar elastolytic mechanisms destroying lung pa-
renchyma to cause emphysema andweakening the aorta wall, however
it requires further investigation.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2021.02.017.
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